Evidence map›Paper›PMID 18725975›Full record

ArticlePloS one2008

Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin.

José Manuel Cuevas, Manuela Torres-Puente, Nuria Jiménez-Hernández, María Alma Bracho, Inmaculada García-Robles, Boris Wrobel, Fernando Carnicer, Juan del Olmo, Enrique Ortega, Andrés Moya and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. The Role of the RNA-RNA Interactome in the Hepatitis C Virus Life Cycle.International journal of molecular sciences · 2020
    Review
  2. Article
  3. Article
  4. Interferons as therapeutic agents for infectious diseases.Infectious disease clinics of North America · 2011
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

José Manuel CuevasInstituto Cavanilles de Biodiversidad y Biología Evolutiva and Departamento de Genética, Universidad de Valencia, Valencia, Spain.
Manuela Torres-Puente
Nuria Jiménez-Hernández
María Alma Bracho
Inmaculada García-Robles
Boris Wrobel
Fernando Carnicer
Juan del Olmo
Enrique Ortega
Andrés Moya
Fernando González-Candelas
Universitat de València · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESHospital Clínico Universitario de Valencia · ESHospital General Universitario de Alicante Doctor Balmis · ESHospital General Universitario De Valencia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present an analysis of the selective forces acting on two hepatitis C virus genome regions previously postulated to be involved in the viral response to combined antiviral therapy. One includes the three hypervariable regions in the envelope E2 glycoprotein, and the other encompasses the PKR binding domain and the V3 domain in the NS5A region. We used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples were obtained before initiation of therapy and after 6 or/and 12 months of treatment. A range of 25-100 clones per patient, genome region and time sample were sequenced. These were used to detect general patterns of adaptation, to identify particular adaptation mechanisms and to analyze the patterns of evolutionary change in both genome regions. These analyses failed to detect a common adaptive mechanism for the lack of response to antiviral treatment in these patients. On the contrary, a wide range of situations were observed, from patients showing no positively selected sites to others with many, and with completely different topologies in the reconstructed phylogenetic trees. Altogether, these results suggest that viral strategies to evade selection pressure from the immune system and antiviral therapies do not result from a single mechanism and they are likely based on a range of different alternatives, in which several different changes, or their combination, along the HCV genome confer viruses the ability to overcome strong selective pressures.

Indexed as

Genetic VariationAntiviral AgentsComplementarity Determining RegionsEvolution, MolecularGenome, ViralHepacivirusHepatitis CHumansInterferon-alphaInterferon alpha-2PhylogenyRecombinant ProteinsRibavirinRNA-Dependent RNA PolymeraseViral Nonstructural ProteinsAntiviral AgentsComplementarity Determining RegionsInterferon-alphaInterferon alpha-2NS-5 protein, hepatitis C virusRecombinant ProteinsRibavirinRNA-Dependent RNA PolymeraseViral Nonstructural Proteins

Identifiers

PMID18725975
PMCPMC2518109
OpenAlexW2089773825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.